6505-- Denosumab Injections

The Department of Veterans Affairs (VA) National Acquisition Center plans to release a Request for Proposal (RFP) for the procurement of Denosumab Injection, intended to serve multiple federal healthcare entities including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted procurement aims to award a single contract to a responsible offeror capable of providing a continuous supply of Denosumab, covering two dosage strengths: 60 mg and 120 mg injections, with estimated annual usage of approximately 22,737 and 5,472 units respectively. The contract will have a one-year base period and four additional one-year option periods, with distribution managed through the VA and DoD Pharmaceutical Prime Vendor Programs. The solicitation will be issued electronically in compliance with FAR Part 12, with a release date around April 17, 2026, and a response deadline of May 5, 2026. Offerors must submit products under the exact drug name as labeled, with a unique National Drug Code (NDC), and are prohibited from relabeling products with other manufacturers' labels. All proposed covered drugs must comply with specific federal pricing requirements, including established Federal Ceiling Prices (FCPs) in line with 38 U.S.C. § 8126, and be included on the offeror’s Federal Supply Schedule contracts. Biosimilar products must be FDA-licensed and meet biosimilar criteria as outlined by federal law. If offering both vial and syringe presentations for the same strength, the contractor must propose the same price for both formats, and any alternate presentations introduced after contract award will be added at the contract price. Interested entities are encouraged to monitor SAM.gov for solicitation documents and updates.